This trial is testing the safety of combining the oral chemotherapy drug capecitabine with
radio-labeled microspheres injected directly into the liver.
Patients with adequate liver function and performance status in whom liver-directed therapy
and capecitabine would be appropriate are eligible for this clinical trial.
- Adequate liver function
- Adequate performance status
- Significant extrahepatic disease